Company / Operating Income
ELITE PHARMACEUTICALS INC /NV/ Operating Income History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$19.6M
FY2024
5-year range
$3.7M / $19.6M
FY2020-FY2024
Trend
+81.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 9 years, ranging from -$9M in FY2018 to $20M in FY2024.
Based on SEC 10-K filings.
$20M in FY2024 with a 3-year CAGR of +56.9%.
Improved from $4M to $20M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- +56.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +56.9%, indicating consistent growth.
- In FY2024, operating income increased 81.7% year-over-year.
- Lowest operating income in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.19 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $19.6M | +81.7% |
| FY2023 | $10.8M | +193.5% |
| FY2022 | $3.7M | -27.5% |
| FY2021 | $5.1M | +140.9% |
| FY2020 | $2.1M | +192.1% |
| FY2019 | -$2.3M | +75.0% |
| FY2018 | -$9.2M | -1.2% |
| FY2017 | -$9.1M | -23.0% |
| FY2016 | -$7.4M | +11.6% |
As of FY2024 · SEC 10-K · Updated Jun 29, 2026